Durham, North Carolina (November 09, 2022) -- KBI Biopharma & Selexis (“KBI”) today announced the appointment of JSR Life Sciences President Tim Lowery as interim CEO, effective immediately. Mr. Lowery, who joined JSR in 1996, brings extensive...
Read More
KBI and Selexis welcome Abdelaziz Toumi, Ph.D., as Chief Business Officer. Toumi will lead Global Business Development for KBI and Selexis as well as...
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel...
GENEVA, June 14, 2022— KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated...
EXPANDS US-BASED MAMMALIAN CELL CULTURE OPERATIONS
KBI TO PRODUCE MATERIAL FOR USE IN FUTURE EXPECTED PHASE 2 CLINICAL TRIAL OF ORAGENICS’ INTRANASAL VACCINE CANDIDATE
KBI BIOPHARMA COMPLETES EUROFINS DISCOVERX PRODUCTS SPECIALIZED BIOASSAY CERTIFICATION PROGRAM Companies will work together on critical components...
Adalta Secures AD-214 Resupply Under KBI Biopharma MSA
SELEXIS AND KBI BIOPHARMA ENTER INTO AGREEMENTS WITH IMMATICS FOR INTEGRATED APPROACH TO ADVANCE IMMATICS TCR BISPECIFIC PROGRAM TOWARDS IND
KBI BIOPHARMA ENTERS COMMERCIAL MANUFACTURING AGREEMENT WITH AM-PHARMA TO PREPARE FOR THE COMMERCIAL LAUNCH OF LEAD PROGRAM IN ACUTE KIDNEY DISEASE
